- Alternative Therapies
- Blood, Heart and Circulation
- Bones and Muscles
- Brain and Nerves
- Child health
- Cosmetic Surgery
- Digestive System
- Disorders and Conditions
- Drugs Approvals and Trials
- Environmental Health
- Ear, Nose and Throat
- Eyes and Vision
- Female Reproductive
- Genetics and Birth Defects
- Geriatrics and Aging
- Immune System
- Kidneys and Urinary System
- Life style and Fitness
- Lungs and Breathing
- Male Reproductive
- Medical Breakthroughs
- Mental Health and Behavior
- Metabolic Problems
- Oral and Dental Health
- Pregnancy and Childbirth
- Public Health and Safety
- Sexual Health
- Skin, Hair and Nails
- Substance Abuse
- Surgery and Rehabilitation
Chemical found in crude oil linked to congenital heart disease
Study shows fetal exposure to solvents may damage heart
DENVER – While it may be years before the health effects of the 2010 oil spill in the Gulf of Mexico are known, a new study shows that fetal exposure to a chemical found in crude oil is associated with an increased risk of congenital heart disease (CHD).
The study, to be presented Saturday, April 30, at the Pediatric Academic Societies (PAS) annual meeting in Denver, also showed that babies who had been exposed in utero to a chemical found in cleaning agents and spot removers were at increased risk of CHD.
Environmental causes of CHD have been suspected, and animal studies have suggested certain chemicals may cause CHD, a problem with the heart's structure and function due to abnormal heart development before birth.
"Congenital heart disease is a major cause of childhood death and life-long health problems," said D. Gail McCarver, MD, FAAP, lead author of the study and professor of pediatrics at the Medical College of Wisconsin and Children's Research Institute, Milwaukee. "Thus, identifying risk factors contributing to CHD is important to public health."
Dr. McCarver and her colleagues sought to determine whether human fetal exposure to solvents is associated with increased risk for CHD. The researchers tested samples of meconium, or fetal stool, from 135 newborns with CHD and 432 newborns without CHD. Meconium has been used to assess fetal exposure to illicit drugs such as cocaine. Seventeen compounds were measured in meconium samples using methods that detect very low levels of chemicals.
Additional data collected included race of the mothers and infants, family history for CHD, and maternal alcohol, tobacco, vitamin and drug use.
Infants with chromosomal abnormalities known to be linked to CHD, and babies of diabetic mothers were excluded from the study.
Results showed that 82 percent of infants had evidence of intrauterine exposure to one or more of the solvents measured.
Among white infants, but not black infants, fetal exposure to ethyl benzene was associated with a four-fold increased risk of CHD. In addition, exposure to trichloroethylene was associated with a two-fold increased risk for CHD among white infants and an eight-fold increased risk among black infants.
"This is the first report that exposure to ethyl benzene, a compound present in crude oil, was associated with CHD," Dr. McCarver said. Humans also can be exposed to ethyl benzene through inhalation of motor vehicle emissions, gasoline pump vapors and cigarette smoke.
"The association with ethyl benzene exposure is concerning, particularly considering recent oil spills," she said. "However, additional confirmatory studies are needed."
The study also adds to existing concerns about trichloroethylene (TCE). "This is of particular importance because TCE is a commonly used degreasing agent, which also is present in many cleaners and spot removers. TCE also has been the most common chemical identified around hazardous waste sites," Dr. McCarver said.
"Limiting known maternal exposure to this compound during early pregnancy appears prudent, particularly among those at increased CHD risk," Dr. McCarver concluded.
To view the abstract, go to http://www.abstracts2view.com/pas/view.php?nu=PAS11L1_1736.
The Pediatric Academic Societies (PAS) are four individual pediatric organizations who co-sponsor the PAS Annual Meeting – the American Pediatric Society, the Society for Pediatric Research, the Academic Pediatric Association, and the American Academy of Pediatrics. Members of these organizations are pediatricians and other health care providers who are practicing in the research, academic and clinical arenas. The four sponsoring organizations are leaders in the advancement of pediatric research and child advocacy within pediatrics, and all share a common mission of fostering the health and well being of children worldwide. For more information, visit www.pas-meeting.org.